SMT aims to be one of top-three stent players in Europe, eyes Tier-I cities

Currently, SMT is the number 2 player in the Rs 12-20 bn Indian stent market and has a less than 5% share in the international market

Morgan Stanley and Samara Capital-backed cardiac stent manufacturer Sahajanand Medical Technologies (SMT) is banking on a recent global study, which showed that its Supraflex stents are clinically on a par with Abbott's Xience stents, to aim for the top spot in the domestic market and also be among the top three players in Europe. 

Surat-based SMT is at present the No. 2 player in the Rs 12-20 billion Indian stent market and has a less than 5 per cent share in the international market. 

Ganesh P Sabat, chief executive officer of SMT, claimed the TALENT study showed that with Supraflex